98%
921
2 minutes
20
Non-small cell lung cancer (NSCLC) remains one of the most lethal malignancies worldwide, highlighting the urgent need for the development of novel multifunctional therapeutic strategies. In this study, a bioinspired nanocomposite drug delivery system was designed and constructed by covalently modifying propylene glycol alginate (PGA) with a microbial-derived coumarin compound (Compound 1) and a fluorinated small molecule (Compound 2), followed by assembly with the silane-based crosslinker ATPMS. The system was subsequently loaded with Dendrobium extract to produce the final nanocomposite material, 2-PGA-1-ATPMS@Dendrobium. This platform exhibited excellent biocompatibility, enhanced cellular uptake, and significant anti-proliferative effects against NSCLC cells. Mechanistic investigations revealed that the nanomaterial induced tumor cell pyroptosis by upregulating the expression of Caspase-1 and GSDMD and promoting the transcription of pro-inflammatory cytokines. Moreover, the nanocomposite demonstrated ultra-sensitive ratiometric fluorescence detection of Cu²⁺ ions, with a detection limit as low as 0.068 nM. Given the critical role of copper ions in inducing cuproptosis and their involvement in tumor progression, this dual-functional nanoplatform presents promising potential for both early diagnosis and targeted treatment of NSCLC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10895-025-04548-9 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Geriatric Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008.
Objectives: Non-small cell lung cancer (NSCLC) is associated with poor prognosis, with 30% of patients diagnosed at an advanced stage. Mutations in the and genes are important prognostic factors for NSCLC, and targeted therapies can significantly improve survival in these patients. Although tissue biopsy remains the gold standard for detecting gene mutations, it has limitations, including invasiveness, sampling errors due to tumor heterogeneity, and poor reproducibility.
View Article and Find Full Text PDFCurr Drug Targets
September 2025
Center for Developmental Biology, School of Life Science, Anhui Agricultural University, 230036, Hefei, China.
Lung cancer, particularly non-small cell lung cancer, is a leading cause of global mortality, with many cases diagnosed at advanced stages. The Toll-Like Receptor (TLR) signaling pathway plays a crucial role in linking inflammation to lung cancer progression, with both pro-tumor and anti-tumor effects. This perspective delves into the complex functions of TLR proteins in lung cancers, elucidating their involvement in tumor growth, angiogenesis, and metastasis.
View Article and Find Full Text PDFCurr Cancer Drug Targets
September 2025
Department of Critical Care Medicine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, 358 Datong Road, Pudong New District, Shanghai 200137, China.
Introduction: The incidence of brain metastases in patients diagnosed with ad-vanced lung cancer is high, drawing significant attention to the risk factors associated with this progression.
Methods: A total of 252 advanced non-small cell lung cancer (NSCLC) patients with brain metastases were enrolled in this study between July 2018 and December 2023 from our hos-pital. Additionally, driver genes, including EGFR, ALK, ROS1, KRAS, and RET, were doc-umented.
Korean J Clin Oncol
August 2025
Department of Clinical Medicine (IKM), University of Copenhagen, Copenhagen, Denmark.
Approximately 3% to 5% of individuals with oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene develop non-small cell lung cancer (NSCLC). Brigatinib, a potent next-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated significant systemic and intracranial responses, as well as improved progression-free survival, with an acceptable safety profile. According to European Society for Medical Oncology guidelines patients with ALK translocation and performance status 0-3 can be offered 1st line treatment with TKI (brigatinib, alectinib, or lorlatinib).
View Article and Find Full Text PDFBioorg Chem
August 2025
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:
HDAC inhibitors, which have been proven to be effective for some cancers, have potential as treatments for Non-small cell lung cancer (NSCLC). Building on the core structure of the highly selective HDAC6 inhibitor J22352, we modified various zinc-binding groups of this inhibitor. The resulting compounds 1-8 were designed and synthesized to explore potential derivatives and assess their effects on NSCLC bioactivity.
View Article and Find Full Text PDF